ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

biological signal processing ltd. - צוות טכני - the hyperq™ ad software is intended to be used as an aid to stress ecg test for early detection of ischemia by means of analysis of high frequency components present within the central portion of the qrs complex

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 150 mg / 1 ml - emicizumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 30 mg / 1 ml - emicizumab

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - everolimus - טבליה - everolimus 10 mg - everolimus

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - everolimus - טבליה - everolimus 2.5 mg - everolimus

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - everolimus - טבליה - everolimus 5 mg - everolimus

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - everolimus - טבליה - everolimus 7.5 mg - everolimus

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליות ניתנות לפיזור - everolimus 2 mg - everolimus